Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

NCT06337318 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06337318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06337318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Recruiting
Start date
October 23, 2024
Completion date
March 31, 2032
Enrollment
600 (estimated)
Sites
286

Conditions

As the registry lists them; a condition with its own page is linked.

classic follicular lymphoma, follicular lymphoma with unusual cytological features